Results 171 to 180 of about 32,657 (252)

Underweight in Young Adult Women as a Dynamic Nutritional State: Evidence from Four Complementary Longitudinal Methods. [PDF]

Nutrients
Iizuka K, Matsuura H, Yanagi K, Hiraiwa E, Sato Y, Kaito K, Yamamoto-Wada R, Deguchi K, Naruse H.   +8 more
europepmc   +1 more source

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

Advanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang, Dandan Zong, Rui Liu, Yubo Wang, Qingqing Gu, Yao Yao, Wenfang Zheng, Mengmeng Yuan, Simeng Wang, Rongrong Cui, Daxu Li, Siwen Dang, Peng Hou   +12 more
wiley   +1 more source

A comparison of Kaplan-Meier-based inverse probability of censoring weighted regression methods. [PDF]

Lifetime Data Anal
Overgaard M.
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Risk functions with outcome measurement error. [PDF]

Biostatistics
Edwards JK, Cole SR, Zivich PN, Ackerman B, Napravnik S, Henderson H, Lash T, Shook-Sa BE.   +7 more
europepmc   +1 more source

Restriction of Individual Branched‐Chain Amino Acids has Distinct Effects on the Development and Progression of Alzheimer's Disease in 3xTg Mice

Advanced Science, EarlyView.
Protein restriction (PR) slows Alzheimer's disease (AD) in mice, and other benefits of PR are due to decreased branched‐chain amino acids (BCAAs). We show that restricting any BCAA has benefits, with sex‐ and BCAA‐specific impacts on pathology, molecular signaling, and cognition.
Reji Babygirija, Cara L. Green, Michelle M. Sonsalla, Izabelle Marie F. Le, Fan Xiao, Sarah Yandell, Mariah F. Calubag, Michaela E. Trautman, Anna Tobon, Ryan Matoska, Chung‐Yang Yeh, Charles I. Opara, Isaac Grunow, Diana Vertein, Sophia Schlorf, Bailey A. Knopf, Michael J. Rigby, David A. Harris, Mark P. Keller, Alan D. Attie, Luigi Puglielli, Cholsoon Jang, Dudley W. Lamming   +22 more
wiley   +1 more source

Structural and Non-Structural Deterioration After Biological Aortic Valve Replacement: Long-Term Outcomes of 918 High-Risk Patients. [PDF]

J Cardiovasc Dev Dis
Hlavička J, Landgraf J, Winter A, von Zeppelin M, Ilgin Y, Salem R, Hecker F, Walther T, Holubec T.   +8 more
europepmc   +1 more source

Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor‐Associated Neutrophils to Sensitize Immunotherapy

Advanced Science, EarlyView.
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang, Xinyu Qu, Tingting Ren, Tong Wu, Weiyong Gu, Jingxin Ding, Keqin Hua, Junjun Qiu   +7 more
wiley   +1 more source

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials. [PDF]

NPJ Precis Oncol
Nichetti F, Hüllein J, du Rusquec P, Pleasance E, Chen L, Mock A, Horak P, Ambrosini P, Rota S, Niger M, Agnelli L, Tinè G, Edelmann D, Le Tourneau C, Laskin J, Pruneri G, Wang C, Hübschmann D, de Braud F, Fröhling S, Mariani L.   +20 more
europepmc   +1 more source

Halofuginone is a Molecular Glue Degrader of Integrin β4

Advanced Science, EarlyView.
Integrin β4 overexpression is linked to aggressive tumors and poor prognosis, but targeted therapies are lacking. We identified halofuginone (HF) as a molecular glue degrader that promotes integrin β4 degradation via the CRL4BWDR18 E3 ligase. HF suppresses tumor progression in vitro and in vivo, offering a new strategy for targeting oncogenic ...
Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan   +8 more
wiley   +1 more source